Aa
A
A
Close
Avatar universal
AbbVie 96 percent SVR(12) IN Treatment-Experienced Patients with Genotype 1A
NORTH CHICAGO, Ill., Dec. 10, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients with chronic, genotype 1 (GT1) hepatitis C virus (HCV) infection. In the 394-patient SAPPHIRE-II study, 96 percent of patients who previously failed pegylated interferon and ribavirin treatment, including approximately 49 percent of who were prior null responders, achieved sustained virologic response at 12 weeks (SVR12) with the regimen. The majority of patients were GT1a, considered a difficult-to-treat subtype, and the SVR12 rates of GT1a and GT1b were 96 percent and 97 percent, respectively.  MORE INFO HERE

http://hcvadvocate.blogspot.ca/2013/12/abbvie-demonstrates-96-percent-svr12-in.html
Cancel
2 Answers
Page 1 of 1
Avatar universal
Have been following this trial and yes the results of the triple DAA combo is very encouraging.

Thx. for posting ...
Will
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
4113881 tn?1415853876
Interesting stuff, thanks for posting it.
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Your Answer
Avatar universal
Answer
Do you know how to answer? Tap here to leave your answer...
Answer
Answer
Post Answer
A
A
Recent Activity
406584 tn?1399591666
Blank
Dee1956, and 10356 commented on dominosarah's status
8 hrs ago
317787 tn?1473362051
Blank
Dee1956 commented on atthebeach's status
Sep 27
317787 tn?1473362051
Blank
Dee1956 commented on meegWpaw's status
Sep 27
Blank
Weight Tracker
Track your weight over time
Start Tracking Now
Top Hepatitis Answerers
317787 tn?1473362051
Blank
DC
163305 tn?1333672171
Blank
Rural Mural, CA
446474 tn?1446351282
Blank
San Francisco, CA
Avatar universal
Blank
1747881 tn?1358189534
Blank
Greeley, CO
2059648 tn?1439770265
Blank
Hepatitis C Community Resources